1
|
Gonzalez-Lara L, Bonsang B, Zimmermann U, Blom A, Chapalain M, Tchakerian A, Serra M, Aouidad I, Chaplain L, Roger A, Longvert C, Saiag P, Funck-Brentano E. Formalin-fixed tissue Mohs surgery (slow Mohs) for trichoblastic carcinoma. J Eur Acad Dermatol Venereol 2022; 36:e827-e828. [PMID: 35686623 DOI: 10.1111/jdv.18309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2022] [Accepted: 05/18/2022] [Indexed: 11/30/2022]
Affiliation(s)
- L Gonzalez-Lara
- Department of Dermatology, Ambroise Paré Hospital, Boulogne-Billancourt, France
| | - B Bonsang
- Research Unit EA 4340 "Biomarkers in Cancerology and in Hemato-oncology", University of Versailles-Saint-Quentin-en-Yvelines, Université Paris-Saclay, Boulogne-Billancourt, France.,Department of Pathology, Ambroise Paré Hospital, Boulogne-Billancourt, France
| | - U Zimmermann
- Research Unit EA 4340 "Biomarkers in Cancerology and in Hemato-oncology", University of Versailles-Saint-Quentin-en-Yvelines, Université Paris-Saclay, Boulogne-Billancourt, France.,Department of Pathology, Ambroise Paré Hospital, Boulogne-Billancourt, France
| | - A Blom
- Department of Dermatology, Ambroise Paré Hospital, Boulogne-Billancourt, France
| | - M Chapalain
- Department of Dermatology, Ambroise Paré Hospital, Boulogne-Billancourt, France
| | - A Tchakerian
- Department of Dermatology, Ambroise Paré Hospital, Boulogne-Billancourt, France
| | - M Serra
- Department of Dermatology, Ambroise Paré Hospital, Boulogne-Billancourt, France
| | - I Aouidad
- Department of Dermatology, Ambroise Paré Hospital, Boulogne-Billancourt, France
| | - L Chaplain
- Department of Dermatology, Ambroise Paré Hospital, Boulogne-Billancourt, France
| | - A Roger
- Department of Dermatology, Ambroise Paré Hospital, Boulogne-Billancourt, France
| | - C Longvert
- Department of Dermatology, Ambroise Paré Hospital, Boulogne-Billancourt, France
| | - P Saiag
- Department of Dermatology, Ambroise Paré Hospital, Boulogne-Billancourt, France.,Research Unit EA 4340 "Biomarkers in Cancerology and in Hemato-oncology", University of Versailles-Saint-Quentin-en-Yvelines, Université Paris-Saclay, Boulogne-Billancourt, France
| | - E Funck-Brentano
- Department of Dermatology, Ambroise Paré Hospital, Boulogne-Billancourt, France.,Research Unit EA 4340 "Biomarkers in Cancerology and in Hemato-oncology", University of Versailles-Saint-Quentin-en-Yvelines, Université Paris-Saclay, Boulogne-Billancourt, France
| |
Collapse
|
2
|
Molinier R, Roger A, Genet B, Blom A, Longvert C, Chaplain L, Fort M, Saiag P, Funck‐Brentano E. Impact of the French COVID-19 pandemic lockdown on newly diagnosed melanoma delay and severity. J Eur Acad Dermatol Venereol 2022; 36:e164-e166. [PMID: 34753221 PMCID: PMC8657330 DOI: 10.1111/jdv.17802] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2021] [Accepted: 11/03/2021] [Indexed: 01/19/2023]
Affiliation(s)
- R. Molinier
- Department of General and Oncologic DermatologyAmbroise‐Paré hospitalAP‐HPBoulogne‐BillancourtFrance
| | - A. Roger
- Department of General and Oncologic DermatologyAmbroise‐Paré hospitalAP‐HPBoulogne‐BillancourtFrance,Research unit EA4340 “Biomarkers and clinical trials in oncology and onco‐hematology”Versailles‐Saint‐Quentin‐en‐Yvelines UniversityParis‐Saclay UniversityVersaillesFrance
| | - B. Genet
- Department of Statistics and Methodology on Biomedical ResearchKremlin‐Bicêtre UniversityParis‐Saclay UniversityLe Kremlin‐BicêtreFrance
| | - A. Blom
- Department of General and Oncologic DermatologyAmbroise‐Paré hospitalAP‐HPBoulogne‐BillancourtFrance,Research unit EA4340 “Biomarkers and clinical trials in oncology and onco‐hematology”Versailles‐Saint‐Quentin‐en‐Yvelines UniversityParis‐Saclay UniversityVersaillesFrance
| | - C. Longvert
- Department of General and Oncologic DermatologyAmbroise‐Paré hospitalAP‐HPBoulogne‐BillancourtFrance,Research unit EA4340 “Biomarkers and clinical trials in oncology and onco‐hematology”Versailles‐Saint‐Quentin‐en‐Yvelines UniversityParis‐Saclay UniversityVersaillesFrance
| | - L. Chaplain
- Department of General and Oncologic DermatologyAmbroise‐Paré hospitalAP‐HPBoulogne‐BillancourtFrance
| | - M. Fort
- Department of General and Oncologic DermatologyAmbroise‐Paré hospitalAP‐HPBoulogne‐BillancourtFrance
| | - P. Saiag
- Department of General and Oncologic DermatologyAmbroise‐Paré hospitalAP‐HPBoulogne‐BillancourtFrance,Research unit EA4340 “Biomarkers and clinical trials in oncology and onco‐hematology”Versailles‐Saint‐Quentin‐en‐Yvelines UniversityParis‐Saclay UniversityVersaillesFrance
| | - E. Funck‐Brentano
- Department of General and Oncologic DermatologyAmbroise‐Paré hospitalAP‐HPBoulogne‐BillancourtFrance,Research unit EA4340 “Biomarkers and clinical trials in oncology and onco‐hematology”Versailles‐Saint‐Quentin‐en‐Yvelines UniversityParis‐Saclay UniversityVersaillesFrance
| |
Collapse
|
3
|
Bouchereau S, Chaplain L, Fort M, Beauchet A, Sidibé T, Chapalain M, Gonzalez-Lara L, Longvert C, Blom A, Saiag P, Funck-Brentano E. Impact of prior treatment with immune checkpoint inhibitors on dacarbazine efficacy in metastatic melanoma. Br J Cancer 2021; 125:948-954. [PMID: 34262147 DOI: 10.1038/s41416-021-01486-8] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2021] [Revised: 06/07/2021] [Accepted: 07/01/2021] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND Despite its low efficacy, chemotherapy with dacarbazine remains an option in metastatic melanoma patients after failure of immune checkpoint inhibitors (ICI) ± targeted therapy. Some observations suggested an increased efficacy of chemotherapy in melanoma or lung cancer patients previously treated with ICI; we aimed to evaluate the efficacy of dacarbazine in a controlled-group study of patients pre-treated or not with ICI. METHODS We retrospectively collected data from all consecutive patients treated with dacarbazine for advanced cutaneous melanoma without brain metastasis, in our skin cancer centre between June 2006 and September 2019. The primary endpoint was progression-free survival (PFS); secondary endpoints were overall response rates (ORR), overall survival (OS) and safety of dacarbazine. RESULTS Among 72 patients, 17 (23.6%) received dacarbazine after ICI and 55 (76.3%) without prior ICI. Despite less favourable prognostic factors in patients ICI-pre-treated, median PFS was 4.27 months (range 0.89-43.69) in this group versus 2.04 months (range 1.25-39.25) P = 0.03 in non-ICI-pre-treated patients; ORR were 35.3% and 12.7%, respectively. The median OS and the occurrence of adverse events were similar in both groups. CONCLUSION Dacarbazine seems to offer a short-lived benefit in patients with progressive advanced disease despite ICI (±targeted therapy), and could be an alternative before considering best supportive care.
Collapse
Affiliation(s)
- Sarah Bouchereau
- Department of General and Oncologic Dermatology, Ambroise Paré Hospital, AP-HP, Boulogne-Billancourt, France
| | - Louise Chaplain
- Department of General and Oncologic Dermatology, Ambroise Paré Hospital, AP-HP, Boulogne-Billancourt, France.,Research unit EA4340 'Biomarkers and clinical trials in cancerology and onco-hematology', Versailles-Saint-Quentin-en-Yvelines University, Paris-Saclay University, Boulogne-Billancourt, France
| | - Magali Fort
- Department of General and Oncologic Dermatology, Ambroise Paré Hospital, AP-HP, Boulogne-Billancourt, France
| | - Alain Beauchet
- Department of Public Health, GHU Paris-Saclay, AP-HP, Boulogne-Billancourt, France
| | - Thomas Sidibé
- Department of Pharmacy, Ambroise Paré Hospital, AP-HP, Boulogne-Billancourt, France
| | - Marie Chapalain
- Department of General and Oncologic Dermatology, Ambroise Paré Hospital, AP-HP, Boulogne-Billancourt, France
| | - Leire Gonzalez-Lara
- Research unit EA4340 'Biomarkers and clinical trials in cancerology and onco-hematology', Versailles-Saint-Quentin-en-Yvelines University, Paris-Saclay University, Boulogne-Billancourt, France
| | - Christine Longvert
- Department of General and Oncologic Dermatology, Ambroise Paré Hospital, AP-HP, Boulogne-Billancourt, France.,Research unit EA4340 'Biomarkers and clinical trials in cancerology and onco-hematology', Versailles-Saint-Quentin-en-Yvelines University, Paris-Saclay University, Boulogne-Billancourt, France
| | - Astrid Blom
- Department of General and Oncologic Dermatology, Ambroise Paré Hospital, AP-HP, Boulogne-Billancourt, France.,Research unit EA4340 'Biomarkers and clinical trials in cancerology and onco-hematology', Versailles-Saint-Quentin-en-Yvelines University, Paris-Saclay University, Boulogne-Billancourt, France
| | - Philippe Saiag
- Department of General and Oncologic Dermatology, Ambroise Paré Hospital, AP-HP, Boulogne-Billancourt, France.,Research unit EA4340 'Biomarkers and clinical trials in cancerology and onco-hematology', Versailles-Saint-Quentin-en-Yvelines University, Paris-Saclay University, Boulogne-Billancourt, France
| | - Elisa Funck-Brentano
- Department of General and Oncologic Dermatology, Ambroise Paré Hospital, AP-HP, Boulogne-Billancourt, France. .,Research unit EA4340 'Biomarkers and clinical trials in cancerology and onco-hematology', Versailles-Saint-Quentin-en-Yvelines University, Paris-Saclay University, Boulogne-Billancourt, France.
| |
Collapse
|
4
|
Charvet E, Kramkimel N, Chaplain L, Gantzer A, Kassem O, Longvert C, Blom A, Dupin N, Aractingi S, Hamon M, Zimmermann U, Emile JF, Sohier P, Sidibé T, Saiag P, Funck-Brentano E. Second primary cutaneous melanoma in patients with advanced melanoma treated with anti-programmed-death-receptor-1 monoclonal antibodies. Br J Dermatol 2020; 184:746-748. [PMID: 33098566 DOI: 10.1111/bjd.19629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2020] [Revised: 10/20/2020] [Accepted: 10/21/2020] [Indexed: 01/10/2023]
Affiliation(s)
- E Charvet
- Departments of, Department of, General and Oncologic Dermatology, Ambroise-Paré Hospital, AP-HP, Boulogne-Billancourt, France
| | - N Kramkimel
- Departments of, Department of, Dermatology, Cochin Hospital, AP-HP, Paris, France
| | - L Chaplain
- Departments of, Department of, General and Oncologic Dermatology, Ambroise-Paré Hospital, AP-HP, Boulogne-Billancourt, France.,EA 4340 'Biomarkers and Clinical Trials in Cancerology and Hemato-oncology', UVSQ, Université Paris-Saclay, Boulogne-Billancourt, France
| | - A Gantzer
- Departments of, Department of, General and Oncologic Dermatology, Ambroise-Paré Hospital, AP-HP, Boulogne-Billancourt, France
| | - O Kassem
- Departments of, Department of, General and Oncologic Dermatology, Ambroise-Paré Hospital, AP-HP, Boulogne-Billancourt, France
| | - C Longvert
- Departments of, Department of, General and Oncologic Dermatology, Ambroise-Paré Hospital, AP-HP, Boulogne-Billancourt, France.,EA 4340 'Biomarkers and Clinical Trials in Cancerology and Hemato-oncology', UVSQ, Université Paris-Saclay, Boulogne-Billancourt, France
| | - A Blom
- Departments of, Department of, General and Oncologic Dermatology, Ambroise-Paré Hospital, AP-HP, Boulogne-Billancourt, France.,EA 4340 'Biomarkers and Clinical Trials in Cancerology and Hemato-oncology', UVSQ, Université Paris-Saclay, Boulogne-Billancourt, France
| | - N Dupin
- Departments of, Department of, Dermatology, Cochin Hospital, AP-HP, Paris, France
| | - S Aractingi
- Departments of, Department of, Dermatology, Cochin Hospital, AP-HP, Paris, France
| | - M Hamon
- Department of, Pathology, Ambroise-Paré Hospital, AP-HP, Boulogne-Billancourt, France
| | - U Zimmermann
- Department of, Pathology, Ambroise-Paré Hospital, AP-HP, Boulogne-Billancourt, France
| | - J-F Emile
- EA 4340 'Biomarkers and Clinical Trials in Cancerology and Hemato-oncology', UVSQ, Université Paris-Saclay, Boulogne-Billancourt, France.,Department of, Pathology, Ambroise-Paré Hospital, AP-HP, Boulogne-Billancourt, France
| | - P Sohier
- Department of, Pathology, Cochin Hospital, AP-HP, Paris, France
| | - T Sidibé
- Department of, Pharmacy, Ambroise-Paré Hospital, AP-HP, Boulogne-Billancourt, France
| | - P Saiag
- Departments of, Department of, General and Oncologic Dermatology, Ambroise-Paré Hospital, AP-HP, Boulogne-Billancourt, France.,EA 4340 'Biomarkers and Clinical Trials in Cancerology and Hemato-oncology', UVSQ, Université Paris-Saclay, Boulogne-Billancourt, France
| | - E Funck-Brentano
- Departments of, Department of, General and Oncologic Dermatology, Ambroise-Paré Hospital, AP-HP, Boulogne-Billancourt, France.,EA 4340 'Biomarkers and Clinical Trials in Cancerology and Hemato-oncology', UVSQ, Université Paris-Saclay, Boulogne-Billancourt, France
| |
Collapse
|
5
|
Gonzalez Lara L, Funck-Brentano E, Bonsang B, Zimmermann U, Blom A, Chapalain M, Tchakerien A, Serra M, Aouidad I, Chaplain L, Roger A, Longvert C, Saiag P. Carcinomes trichoblastiques traités par chirurgie micrographique en paraffine. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.205] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
6
|
Bouchereau S, Chaplain L, Fort M, Beauchet A, Sidibé T, Chapalain M, Gonzalez-Lara L, Longvert C, Blom A, Aouidad I, Saiag P, Funck-Brentano E. Impact de l’immunothérapie sur l’efficacité de la dacarbazine dans le mélanome métastatique. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
7
|
Turquier E, Chaplain L, Fort M, Longvert C, Blom A, Roger A, Chapalain M, Aouidad I, Sidibe T, Beauchet A, Gonzalez-Lara L, Boru B, Saiag P, Funck-Brentano E. Intérêt du PET-scanner avant arrêt des anti-PD-1 dans le mélanome métastatique. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.487] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
8
|
Funck-Brentano E, Charvet E, Chaplain L, Gantzer A, Kassem O, Longvert C, Blom A, Dupin N, Aractingi S, Hamon M, Zimmermann U, Emile JF, Sohier P, Kramkimel N, Saiag P. Second primary melanoma in advanced melanoma patients treated with anti-PD-1 monoclonal antibodies. J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.15_suppl.e22025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e22025 Background: Development of a second primary melanoma (SCPM) has not been reported in melanoma patients treated with anti-PD-1 monoclonal antibodies (mAb), in contrast with those reported in BRAF-inhibitor-treated patients. Our aim was to report arising SCPM in patients with advanced melanoma treated with anti-PD-1 therapy. Methods: Retrospective study, conducted in 2 referral centres, including advanced melanoma patients who developed a SCPM after anti-PD-1 mAb initiation, between September 2010 and May 2019. BRAF or NRAS mutational status was assessed by targeted NGS panels, real-time PCR, and immunohistochemistry. Results: Among a total of 509 patients treated with anti-PD-1 mAb, 4 had a SCPM (incidence: 0.8%; 95%CI: 0.02-1.57%). All patients were treated with nivolumab, in first (N = 3) or second line after progression with BRAF + MEK inhibitors (N = 1). No immune-related adverse event greater than grade 2 according to Common Terminology Criteria for Adverse Events version 5.0. was observed in these 4 cases; a vitiligo-like depigmentation (grade 1) was observed in two patients. The median time from the first nivolumab infusion to the SCPM diagnosis was 17.5 months (range: 5-21). All patients developed the SCPM after achieving a complete response. Nivolumab administration had been discontinued (4 months prior) in one patient. Histology revealed 4 superficial spreading melanomas (SSM): one invasive (without BRAFV600 mutation) and 3 intraepidermal melanomas (2 with a BRAFV600E mutation and one with a NRASQ61H mutation). 3 patients had risk factors for developing multiple melanomas: a dysplastic nevus syndrome, a high number of nevi (≥100 nevi), and a family history of melanoma in first-degree relatives and constitutional heterozygous mutation of exon 2 of the CDKN2A gene. Occurrence of SPCM did not alter advanced melanoma treatment. With a median follow-up of 29 months [range: 18-41] from the first anti-PD-1 mAb infusion, all patients had prolonged CR, and treatment was discontinued in all patients, without relapse after a median 11.5 months [0-18] off therapy. The median duration of nivolumab treatment was 15.5 months [10-24]. Conclusions: Although anti-PD-1 mAb could theoretically decrease the risk of developing another melanoma in metastatic melanoma patients, we found 4 such cases, highlighting the importance of regular clinical screenings for new primary melanoma in patients with metastatic melanoma even when responsive to anti-PD-1 therapy. Immune checkpoint inhibitors do not totally prevent the risk of occurrence a SCPM.
Collapse
Affiliation(s)
- Elisa Funck-Brentano
- Dermatology Department, Ambroise Paré Hospital, APHP, Versailles University – Paris-Saclay, Boulogne-Billancourt, France
| | - Estelle Charvet
- Department of General and Oncologic Dermatology, Ambroise Paré Hospital AP-HP, Boulogne-Billancourt, France
| | - Louise Chaplain
- Department of General and Oncologic Dermatology, Ambroise Paré Hospital AP-HP, Boulogne-Billancourt, France
| | - Amelie Gantzer
- Department of General and Oncologic Dermatology, Ambroise Paré Hospital AP-HP, Boulogne-Billancourt, France
| | - Oula Kassem
- Department of General and Oncologic Dermatology, Ambroise Paré Hospital AP-HP, Boulogne-Billancourt, France
| | - Christine Longvert
- General & Oncology Dermatology, CHU Ambroise Paré APHP & University of Versailles, Boulogne-Billancourt, France
| | - Astrid Blom
- General & Oncology Dermatology, CHU Ambroise Paré APHP & University of Versailles, Boulogne-Billancourt, France
| | - Nicolas Dupin
- Department of Dermatology, Cochin Hospital, Paris, France
| | - Sélim Aractingi
- Department of Dermatology, Cochin Hospital AP-HP, Paris, France
| | - Maxime Hamon
- Department of Pathology, Ambroise Paré Hospital AP-HP, Boulogne-Billancourt, France
| | - Ute Zimmermann
- Department of Pathology, Ambroise Paré Hospital AP-HP, Boulogne-Billancourt, France
| | - Jean-François Emile
- Ambroise Paré Hospital, Versailles University, Boulogne, France, Boulogne, France
| | - Pierre Sohier
- Department of Pathology, Cochin Hospital, AP-HP, Paris, France
| | - Nora Kramkimel
- Assistance Publique–Hôpitaux de Paris, Hôpital Cochin, Paris, France
| | - Philippe Saiag
- Dermatology Department, Ambroise Paré Hospital, APHP, Versailles University – Paris-Saclay, Boulogne-Billancourt, France
| |
Collapse
|
9
|
Charvet E, Chaplain L, Gantzer A, Kassem O, Longvert C, Blom A, Hamon M, Zimmermann U, Emile JF, Saiag P, Funck-Brentano E. Deuxième mélanome primitif sous anti-PD-1 : à propos de 2 cas. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
10
|
Chaplain L, Blom A, Samimi M, Guillot B, Jouary T, Grob JJ, Meyer N, Zehou O, Combemale P, Lebbé C, Jeudy G, Grange F, Lacour P, Dinulescu M, Granel Brocard F, Beneton N, Aubin F, Bens G, De Quatrebarbes J, Steff M, Arnault JP, Le Corre Y, Stefan A, D’Incan M, Kramkimel N, Leccia MT, Thomas Beaulieu D, Maubec E, Robert C, Dreno B, Wierzbicka-Hainaut E, Lenormand C, Saiag P, Mortier L. Carcinome de Merkel : état des lieux du réseau CARADERM. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
11
|
Chaplain L, Moguelet P, Barbaud A, Senet P. Lipœdème du cuir chevelu. Ann Dermatol Venereol 2018; 145:109-112. [DOI: 10.1016/j.annder.2017.08.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2017] [Revised: 05/17/2017] [Accepted: 08/09/2017] [Indexed: 11/30/2022]
|